MARSHALL WACE, LLP

Position in EDIT — Editas Medicine, Inc.

CIK 1318757 LONDON, X0

Position in EDIT

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$519,460

+$207,044 QoQ

Shares Held

210,308

+48.1% QoQ

Ownership

0.215%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2021

12 quarters on record

Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

MARSHALL WACE, LLP holds $2,766,756,129 across 280 Biotechnology names. EDIT ranks #225 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	1,099,318	$363,731,344
2	VRTX	Vertex Pharmaceuticals Inc / Ma	317,058	$141,579,078
3	INCY	Incyte Corp	1,253,138	$117,945,347
4	RPRX	Royalty Pharma plc	2,120,692	$101,729,594
5	RCUS	Arcus Biosciences, Inc.	3,761,437	$81,247,039
6	PTGX	Protagonist Therapeutics, Inc	628,075	$66,199,104
7	ROIV	Roivant Sciences Ltd.	2,246,943	$62,240,320
8	COGT	Cogent Biosciences, Inc.	1,600,168	$61,590,466

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$519,460	210,308	+48.1%	Shares	Other	2026-05-15
2025-06-30	$312,416	142,008	-41.4%	Shares	Other	2025-08-13
2025-03-31	$281,155	242,376	+280.1%	Shares	Other	2025-05-15
2024-09-30	$217,418	63,759	-85.8%	Shares	Other	2024-11-14
2024-06-30	$2,097,543	449,153	-43.2%	Shares	Other	2024-08-14
2024-03-31	$5,871,594	791,320	-28.8%	Shares	Other	2024-05-15
2023-12-31	$11,256,476	1,111,202	-49.4%	Shares	Other	2024-02-14
2023-09-30	$17,119,486	2,194,806	-22.7%	Shares	Other	2023-11-14
2023-06-30	$23,359,348	2,838,317	+11792.2%	Shares	Other	2023-08-14
2022-12-31	$211,700	23,867	+34.7%	Shares	Other	2023-02-14
2022-03-31	$337,129	17,725	-95.4%	Shares	Other	2022-05-16
2021-12-31	$10,264,946	386,627	—	Shares	Other	2022-02-14
No filing history on record for this holder in this stock.